FIELD: medicine.
SUBSTANCE: claimed group of inventions relates to field of medicine. Claimed methods of prevention, treatment or reversion of symptoms of pulmonary fibrous disease in subject, which include introduction to subject of isolated antibody against lysyloxidase-like protein 2 (LOXL), which specifically binds with protein LOXL2 and/or inhibits activity of LOXL2 protein, thereby preventing, curing or inducing reversion of symptoms of pulmonary fibrous, where symptom is increase of number of leucocytes in subject's lungs. Claimed is pharmaceutical composition, which contains isolated anti-LOXL2 antibody and pharmaceutically acceptable filler.
EFFECT: group of inventions provides effective means and methods for prevention, treatment or reversion of symptoms of pulmonary fibrous disease in subject.
9 cl, 19 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING TO LYSYL OXIDASE-LIKE ENZYME-2 (LOXL2), AND METHOD FOR PREPARING THEM | 2011 |
|
RU2549684C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| VAP-1 INHIBITORS ADMINISTRATION FOR FIBROID DISEASES TREATMENT | 2010 |
|
RU2667963C1 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| METHOD OF TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS | 2006 |
|
RU2419450C2 |
| ANTI-CCR2 ANTIBODIES | 2009 |
|
RU2547595C2 |
| MIR-29 MIMETICS AND WAYS OF USE THEREOF | 2015 |
|
RU2712511C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| BLOCK OF CCL18 SIGNALING THROUGH CCR6 AS THERAPEUTIC METHOD OF TREATING FIBROTIC DISEASES AND CANCER | 2011 |
|
RU2609649C2 |
